MTAP and carcinoma: In noninvasive urothelial carcinomas, MTAP expression loss was more common in pTaG2 high‐grade (30.7%) than in pTaG2 low‐grade (10.8%) or pTaG3 carcinomas (17.9%; p < 0.0001).